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The growing obesity pandemic has caused diabetes to become one of the world’s 
leading health concerns. Diabetic individuals often suffer from peripheral neuropathy, 
which is nerve death that typically starts at the extremities and moves from the skin 
inward to deeper tissues. This nerve death causes painful symptoms including tingling, 
stinging, numbness, and others. Current methods to diagnose peripheral neuropathy by 
measuring nerve function are invasive and painful since they target large axons of the 
legs; however, by the time the neuropathy reaches the diagnosable axons, it is often too 
late for intervention. Although no cures for neuropathy are established, aside from 
analgesics for pain, there are options for mitigating worsening of the disease if diagnosed 
early enough (for example, glucose control for diabetic neuropathy). There is a critical 
need for early detection and diagnosis of peripheral neuropathy as obesity and diabetes 
continue to plague the world. Microneedle fabrication is a growing research area, 
especially in transdermal drug delivery due to their minimal invasive, pain-free 
application. The objective of this project is to design a platform using electrically 
conductive microneedles for early detection of peripheral neuropathy. Using these 
needles, neurophysiology can be employed to record electrical signal just below the skin 
to determine the integrity of the nerves to track neuropathy progression. Thus far, 
prototypes of the device have been tested on mice to establish protocols and understand 
the hardware and software, with the goal of eventually developing a usable prototype for 
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PROBLEM STATEMENT AND PROJECT GOALS 
 
 
Diabetes is one of the most prevalent diseases across the world, and peripheral 
neuropathy is a common complication of such. The motivation behind this platform is to 
ultimately be able to diagnose this nerve death sooner than it currently is done in a 
minimally invasive and pain free method. There were several goals of this thesis to get the 
platform started and moving towards a direction to ultimately better the standard of care. 
The overarching aims of the thesis are as follows: 
1. Develop protocols for both the hardware and software obtained to take 
electrical recordings in mice. 
2. Use well-established nerve models to test and troubleshoot the hardware. 
3. Reduce noise of recordings and understand the custom needle electrodes. 
4. Develop staining protocols for a new stain, Luxol Blue, that was obtained. 










Obesity is one of the world’s largest pandemics and health concerns of the 21st 
century. This disease is characterized by excess body fat and can lead to a number of 
health concerns, such as heart disease, joint and limb pain, high blood pressure, diabetes, 
and others. It is clinically defined as a body mass index larger than 30 and biologically, 
there is more white adipose tissue than metabolically normal.1 
There are two different kinds of fats, white adipose tissue (WAT) and brown 
adipose tissue (BAT). These types of adipose tissues have metabolic, cellular, and 
endocrine functions, and are therefore crucial for energy balance of an organism. WAT 
acts as an energy buffer in the body, while BAT is highly oxidative and a main 
contributor to thermogenesis, or the production of heat in the body. An excess of WAT is 
thought to contribute to obesity due to fat accumulation from energy imbalance, whereas 
BAT could have protective effects against obesity. There have been studies aiming to 
“brown” white adipose tissue to combat obesity and prevent diabetes, done by either cold 
stimulation or pharmacological BAT activation, as adipose is a highly dynamic organ 
with an exceptional amount of plasticity.2 However, despite efforts to reverse the effect 





Figure 1. Percentage of adults defined as obese [Body Mass Index (BMI)>30%] as of 
2016. Adapted from Ref [3]. 
 
Diabetes is one of the world’s largest health issues, and is a major disease 
stemming from obesity. As defined by the Center of Disease Control and Prevention, 
diabetes is, “the condition in which the body does not properly process food for use as 
energy”.4 Glucose, or commonly called “sugar”, is an essential energy source in the body 
for many metabolic pathways; however, people with diabetes are unable to properly 
digest glucose. Insulin is a hormone that enables glucose to get inside the cells of our 
body for energy, and the pancreas is the primary manufacturer of this hormone. 
Individuals with diabetes either do not make enough insulin to remove glucose from the 
blood, or the insulin the pancreas produces does not function at full capacity. As a result, 
glucose accumulates in the blood and is not taken in by cells for energy. This 
accumulation can result in serious health effects, including, but not limited to, heart 
disease, neuropathy, blindness, kidney failure, and even death.4  
There are two types of diabetes: Type 1 and Type 2. Type 1 diabetes is less 
common but related to autoimmune, genetic, and environmental factors. Type 2 is much 
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more common, comprising about 90-95% of diabetes cases, and has multiple risk factors 
including aging, obesity, family-related diabetes, race, and more.4 Both types of diabetes 
are typically caused by the loss of β-cell mass, either physically or functionally. β-cells 
are crucial for the response of fluctuating insulin demand. They produce insulin and are 
significantly regulated by glucose to induce metabolic pathways, insulin gene 
transcription, and insulin secretion. As a result, glucose is essential for normal β-cell 
function, regulation, and maintenance. However, in diabetes, the functionality and/or 
quantity of these cells is compromised, resulting in obesity and insulin resistance.5 
The differences between Type 1 and Type 2 diabetes relates to the mechanism by 
which glucose is improperly digested and the process in which the β-cells are lost. For 
instance, Type 1 typically lose β-cells due to an autoimmune process, while Type 2 is the 
result of insulin resistance.6 Essentially, in Type 1 diabetes, the patient does not produce 
enough insulin, so the pathways that allow glucose uptake into the cells is inhibited. In 
Type 2 diabetes, enough insulin is produced, but the cells are resistant to the hormone 
because the insulin receptor is insufficient. This is illustrated in Figure 2, which details 
the differences between Type 1 and Type 2 diabetes and the way that each type affects 
the body. In general, there is no cure for diabetes, but obesity-related Type 2 treatments 




Figure 2. A schematic detailing the differences between a normal, Type 1, and Type 2 
diabetic individual and how insulin and insulin receptors play a role in disease. 
 
One of the quintessential symptoms of diabetes is neuropathy at the peripheral 
limbs, such as an individual’s hands and feet. Peripheral neuropathy is the result of 
damage to the nerves, which can cause things like weakness, numbness and pain; this 
pain can include stabbing, burning or tingling from the extremities. It is estimated that at 
least 22 percent of people with diabetes have moderate to severe peripheral neuropathy, 
and this percentage is only growing.7 From the 22 percent of individuals with diabetes 
that will be affected by neuropathy, the current state of care is that there is no cure, just 
analgesics for pain.7,8  
Neuropathy can be the result of nerve death associated with nerve axons, myelin 
sheath, or both, and can involve motor, sensory, or autonomic nerves.9 In addition to the 
types of nerves that are involved with peripheral neuropathy, the size of nerve fibers, 
either small or large, can be used to categorize neuropathy. When the nerves begin to die 
or become damaged, the communication between neurons is affected, which can lead to 
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more damage down the road. An individual can either have genetic neuropathy or can 
acquire this nerve damage over time due to trauma, vascular disorders, systemic diseases, 
infections, vitamin imbalances, and others. The nerves can become damaged when there 
is compression of the nerves at the periphery with overuse, repetitive stress, or when 
there is impeded blood flow to these neurons. A lack of blood flow to the extremities can 
come from inflammation or blood clots, which ultimately limits oxygen availability and 
results in nerve damage or death.10 Other molecular factors that result in nerve death 
involve toxins or an imbalance of nutrients, such as vitamins, that are critical to healthy 
nerve function.10 Again, there are ways to monitor and alleviate symptoms, but there is 
no treatment to completely reverse the effects of nerve damage and death associated with 
peripheral neuropathy.  
In general, peripheral neuropathy is organized and categorized based on what type 
of nerve fibers are involved, which includes things like the size and how fast nerves 
transmit signals along the axon. There are three types of peripheral nerves: somatic motor 
neurons, somatic sensory neurons, and autonomic neurons. The somatic sensory and 
autonomic functions are based on whether the nerves are involved in things like touch, 
pain, temperature, blood pressure, sweating, and heart rate. There are also classifications 
based on size and diameter of the nerve fibers that are similarly used to classify nerves. 
A-alpha and A-beta nerve fibers are myelinated and have a large diameter. The function 
of these nerves is to carry out motor functions and one’s sense of touch.11 Medium-sized 
diameter nerve fibers that are myelinated are A-gamma nerve fibers which function to 
transmit the motor function to muscle spindles. Small-diameter nerve fibers that are 
myelinated and unmyelinated are categorized as A-delta and C nerve fibers, respectively. 
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These small-diameter fibers carry pain and temperature sensations, as well as transmitting 
the autonomic functions that are involved in small fiber neuropathy typical with nerve 
death associated with diabetes.11 
There are several different types of neuropathies, and diabetic peripheral 
neuropathy (DPN) is just one broad-encompassing term. One type of DPN is small fiber 
neuropathy (SFN), which occurs in the small diameter fibers that are both myelinated and 
unmyelinated. In this type of neuropathy, the large nerve fibers are relatively unaffected 
by neuropathic pathologies, leaving the small nerves in the hands and feet in pain, but 
making detection of neuropathy difficult. In SFN, the small diameter fibers such as A-
delta and C nerve fibers, which are both myelinated and unmyelinated, are affected 
directly. This leaves the larger types of peripheral nerve fibers like A-alpha and A-beta to 
be healthy and unaffected.11 There are several methods that are used to diagnose SFN, but 
the techniques are typically insufficient because of the large axons that are targeted, but 
not affected, in this type of neuropathy. 
Addressing small fiber neuropathy in the clinical setting is difficult to interpret 
and classify. It is defined, loosely, by small fibers with neuropathic pathologies that are 
more severe compared to the large fiber pathologies. For addressing the severity of SFN 
qualitatively, a neurologist can look at the extent of dysesthesia.11 Dysesthesia is a 
disruption of sensory neurons that can lead to sensations of pain, itchiness, burning, or a 
lack of sensation in general.12 Other criterion physicians may use are those that relate 
specifically to neurological damage in small nerve fibers. This criterion can include a loss 
of stimuli perception in the extremities like the toes, a loss of the ability to perceive the 
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environment and the position in that environment (i.e. location and movement), any 
weaknesses of distal limbs, and the general strength of reflexes.11  
Similar to DPN and SFN, the adipose cells can also develop neuropathy. 
Peripheral nerves innervate adipose tissue all throughout the body to communicate with 
the brain, so adipose neural tissue is also prone to neuropathy. When the nerves die back 
from the adipose, control of metabolic function is lost, which progresses the obesity with 
growing adipocyte counts and increased adipose tissue mass. It has been shown and 
measured that through analysis of both human and mouse tissues, neuropathy does occur 
at the nerves innervating WAT, so adipose neuropathy is directly related to the growing 
diabetes epidemic.13 As a result, knowledge of adipose neuropathy is critical for 
understanding peripheral neuropathies associated with obesity and diabetes. 
Additionally, adipose neuropathy is evidence that nerve death moves from the 
skin inward, affecting underlying tissues such as subcutaneous white adipose tissue 
(scWAT). If adipose neuropathy affects adipose metabolic function and control, then 
nerve death continuing to the underlying tissue could prove to be a mechanism of pain 
and disease progression.13 The dying back of nerves in peripheral neuropathy is 
illustrated in Figure 3, where the sensory skin nerves are affected first and die back to 
underlying adipose tissue.  
Figure 3. A schematic of peripheral neuropathy nerve death moving from the skin inward 
as the disease progresses. Reproduced from Magdalena Blaszkiewicz. 
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Despite having no cure, the prevalence of diabetes is not decreasing; in fact, it is 
growing. As shown in Figure 4, there are millions of people worldwide affected by 
diabetes, and the projected numbers of individuals affected with diabetes by 2040 grows 






Figure 4. The worldwide prevalence of diabetes across the globe, with the number of 
individuals affected as of 2015 for each country, and the projected the number of 
individuals affected in 2040. Reproduced from Ref [14]. 
 
With the rising number of diabetic individuals, diagnosis, characterization, and 
quantification of peripheral neuropathy is in increasing demand because current methods 
are generally insufficient.   
 
Diagnostic Tests of Neuropathy 
 
The current standard of care for neuropathy diagnosis involves multiple tests, 
some of which are exceptionally invasive and tedious. The prevalence of neuropathy is 
growing because individuals are often either unable to diagnose neuropathy, or it is 
diagnosed at a time where the disease has progressed too far to intervene in an efficient 
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manner. Additionally, there are currently no cures for neuropathy, nor any way to halt the 
progression of nerve death. The only way to mitigate pain is with analgesics, and 
progression may be slowed with and glucose regulation for diabetic individuals.13 
However, there is a clear clinical need for diagnosis of peripheral neuropathy as current 
methods are inadequate.  
One test a neurologist can perform is an electromyography (EMG), which is 
essentially a test of the connection between one’s nerves and the surrounding muscle. 
This test can be informative to determine if there are problems with nerve signal 
transmissions or if there is nerve or muscle dysfunctions. An electromyography requires a 
needle to penetrate the skin to get directly to the nerves, particularly large axons for a 
larger target, to record how much electric signal is flowing through the muscle.15 When 
an individual undergoes this procedure, a small needle or electrode is inserted in the area 
of interest and an oscilloscope is used to display the electrical activity of the tissue, as 
shown in Figure 5.16 Recordings from the patient would be taken while at rest, during a 
slight contraction, and during a full contraction of the muscle, such as completely 
extending or bending the knee. The electrical activity recorded is compared to healthy 
individuals to determine if there is some sort of nerve disfunction, as the neuropathic 





Figure 5. A schematic outlining potential needle and electrode placement for an EMG 
test. Reproduced from Ref [16]. 
 
A test that is typically coupled with an electromyograph to diagnose neuropathy is 
a nerve conduction velocity (NCV) test. Surface patch electrodes are placed on the skin 
for stimulation, and others are placed at different known locations to measure the 
electrical impulse downstream, as shown in Figure 6.17 The speed of nerve transmission 
is determined from this test and can be telling of decreased nerve conduction, which can 
yield information about axonal myelination, or the lack thereof. The electromyograph can 
help understand the possibility of muscle innervation on these tests, so, collectively, an 
EMG and NCV can be indicative of general nerve health by comparing the speed of 
firing or pattern (i.e. latency time) associated with the nerve to healthy individuals to see 




Figure 6. Nerve conduction velocity procedure setup to show potential surface patch 
electrode placement. Adapted from Ref [17]. 
 
 An EMG and NCV test can be useful for extensive nerve damage, but both are 
invasive and not a guaranteed diagnosis of small fiber neuropathy (SFN). The area of 
needle penetration for an EMG can be sore for several days afterward, similar to the 
feeling of receiving a shot. Multiple needles may be necessary for diagnosis, so the 
discomfort is more than just a single needle in one spot. Bleeding and bruising can also 
occur, and the use of needles poses the threat of infection.15 In addition, receiving these 
tests is inconvenient, as the patient must see a neurologist or other specially trained 
individual; these specialized people are often booked many months in advance. 
Additionally, the results of these tests vary with age; younger individuals generally have 
less myelination than a healthy adult, so the nerve conduction speed in younger people is 
typically slower. Therefore, bridging the gap between age and actual neuropathy-like 
symptoms is a potential limitation of these tests. The electrodes used for an EMG and 
NCV are sensitive to noise and temperature, among other factors, which could influence 
the diagnosis. If the temperature of one’s skin is colder, then the nerve conduction speed 
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and muscular electrical activity can be hindered and affected in a way that could indicate 
neuropathy, but in a healthy individual.18  
Nerve conduction velocity tests are the typical diagnostic tools, but NeuroMetrix 
has developed a less invasive device to evaluate diabetic peripheral neuropathies called 
the DPNCheck. The NCV of the sural nerve, the main nerve through the calf, and the 
response to stimulation is measured and analyzed for neuropathy diagnosis. This device, 
shown in Figure 7, is fairly sensitive to changes in the functionality of the sural nerve.19 
However, by the time the neuropathy spreads from the feet to the calf nerves that are 
measured with this device, it is too late to treat. Additionally, the progression of 
neuropathy to the calves is significantly more painful for the diabetic individual, and such 
pain will only continue to worsen without earlier treatment. 
 
Figure 7. DPNCheck by NeuroMetrix is a device targeted at measuring sural nerve 
conductance. Reproduced from Ref [19]. 
 
Another tool that is currently used to diagnose neuropathy is a skin biopsy. Skin 
biopsies are typically used for small nerve fiber neuropathy, which is one of the most 
difficult to distinguish and recognize. When a patient is receiving a skin biopsy, the area 
is often numbed with lidocaine and the doctor removes a sample of skin. These samples 
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can be taken from any part of the body, such as the fingers and toes, unlike an EMG or 
NCV. The collected skin sample is then analyzed with bright-field 
immunohistochemistry or indirect immunofluorescence to analyze the small nerve fibers 
from that tissue.20 When sectioned and stained with PGP 9.5, a pan-neuronal marker, the 
analyst would be able to observe the nerves present and do necessary calculations on the 
tissue to diagnose peripheral neuropathy, such as density counts per area.20 
Although the pathologist that receives the stained sample could visualize the 
nerves, this technique is not ideal for diagnosing small nerve fiber neuropathy. Skin 
biopsies are very invasive, as they require a skin sample to be scraped and removed from 
the patient.20 Additionally, this technique only assesses morphologies of the nerves 
instead of function. Observation of the nerves in the biopsy that are stained can give 
subjective results if there are discrepancies in opinions of the viewers based on the small 
sample size taken. To really diagnose and assess the extent of neuropathy, ideally, one 
would be able to address function and morphology.  
Yet another method that is used for neuropathy diagnosis is microneurography. 
Microneurography is used to directly record and measure sympathetic action potentials. 
This technique employs skin-surface electrodes, so it is minimally invasive, and can 
measure peripheral nerve conductance and assess the function of small nerve fibers. The 
spectrum of signals collected is relatively broad, so multiple nerve types are 
distinguished. However, microneurography fails to record sympathetic activity for 
diabetic individuals due to potential sensitivity limits. Therefore, this could significantly 
limit the types of patients that can benefit from this diagnostic tool.21,22 
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A relatively new approach of diagnosing peripheral neuropathy is to address 
sudomotor function, or how well an individual’s sweat glands are functioning. The thin, 
unmyelinated C fibers innervate sweat glands, and these are the types of fibers that are 
more greatly influenced in diabetic neuropathy and SFN. C fibers are affected early in 
diabetes and can continue to worsen as the disease and neuropathy progresses. Therefore, 
measuring sweat gland dysfunction could be useful to determine the function and 
integrity of the innervating and surrounding C fibers.23 One device, named Sudoscan, has 
been engineered to diagnose sweat gland dysfunction. This method is minimally invasive 
and pain free, gives a functional assessment of the small fibers, and can detect early 
neuropathy before symptoms arise.23 
The Sudoscan device consists of two electrodes that one’s hands or feet are placed 
on. When an individual has healthy sweat gland dysfunction, and the small fibers are 
innervating these glands, chloride ions are secreted and released to the surface.24 The 
electrodes for the Sudoscan device measures chloride ion conductance, so a high 
conductivity would indicate more sympathetic innervation; therefore, the progression of 
prediabetes and neuropathy can be determined based on chloride conductivity.24,25 
Although this is an indirect functional assessment of the small nerve fibers, peripheral 
nerve conductance cannot be measured, and Sudoscan does not provide an analysis of 
many nerve types that can be affected with peripheral neuropathy. 
Despite several different types of diagnostic techniques and treatments, these tend 
to be insufficient in accurately addressing peripheral neuropathy. Methods such as skin 
biopsies, nerve conduction velocity tests, and an electromyograph are invasive and can 
cause pain for the individual. Additionally, tests like NCV, EMG, and the DPNCheck 
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device can measure nerve conduction velocities of large axons; however, by the time the 
neuropathy reaches these points, it is often too late for intervention and alleviation of the 
pain. Other methods, such as Sudoscan, are indirect measures of neuropathy and could be 
insensitive to small changes as the neuropathy progresses from the skin inward. 
Therefore, there is a clear need for a noninvasive and effective measure of peripheral 
neuropathy detection at the early stages of disease that emphasizes on addressing nerve 
functionality. A promising method for this diagnostic platform is microneedles. 
 
 
The Growing Use of Microneedles 
Microneedles are an emerging technology in biomedical engineering. 
Microneedles are arrays of small, minimally invasive needles that have various uses in 
many industries, such as for transdermal drug delivery (TDD). Microneedles can be 
hollow to administer drugs to bypass the tough epidermal layer, making the speed of drug 
delivery directly into the subcutaneous tissues greatly enhanced, but also the amount that 
is administered to the individual. A general schematic of TDD is illustrated in Figure 8, 
where small drugs can be released directly into the body through the hollow microneedles 







Figure 8. A schematic illustrating transdermal drug delivery with a microneedle array. 
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Microneedle arrays are preferred over single needles because they are painless 
and minimally invasive. There is increased microneedle use in research because there are 
a variety of materials and structures that they can be made of, allowing for very diverse 
uses. There are microneedles made of a variety of materials including, but not limited to, 
silicon, glass, ceramic, hydrogel, polymer, and metal. The length of the needle can also 
be changed by etching and sawing the needles in a particular fashion.27 Additionally, the 
needles can be coated with insulation or other materials to further optimize their use in 
research. Therefore, there is a growing application of microneedles because they are 
relatively customizable due to the characteristics that can be modified, and hold promise 
for many different applications. 
In the creation of a device for early diagnosis of peripheral neuropathy, 
microneedles seem promising. Using microneedles to record electrical signals is a 
relatively novel approach as many researchers and industries are not conducting these 
kinds of experiments. However, coating or making microneedles in a conductive material 
enables them to be used as electrodes, which have the ability to measure electrical 
signals. Biomedical companies such as BlackRock Microsystems sell arrays to measure 
nerve conductance, but typically for brain recordings.28,29 Many experiments that involve 
microneedles recording electrical signals in the body are done with nerves in the central 
nervous system like the brain and spinal cord, rather than the peripheral nervous system. 
Blackrock Microsystems also creates a slant array for peripheral nerve data, but similar to 
the diagnostic tests for neuropathy, these arrays are targeted for implantation in nerves 
like the sciatic and sural nerves in the leg, rather than small fiber nerves at the extremities 
that are affected by peripheral neuropathy first.30 Therefore, the design of this novel 
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neuropathy diagnosis device is to use microneedles to record electrical signals from the 
extremities to determine the functionality of nerves. To do so, an understanding of 




Neurophysiology is a branch of neuroscience and physiology that focuses on the 
physiology and functioning of the nervous system; this field of study often involves 
electrophysiological or other biological tools. Neurons function by establishing 
electrochemical gradients across the cell membrane to generate action potentials; 
essentially, neurons make use of an established transmembrane voltage difference. In 
current nerve conduction studies, typically the voltage of an action potential or the speed 
of transmission is measured. It is known that the resting membrane potential of a neuron 
is about -40 to -90 mV. When a neuron is stimulated or information via synaptic 
terminals is sent, the membrane potential can depolarize, resulting in an action 
potential.31 Measuring the amplitude of voltage from the action potential is one way in 
which researchers test the functionality of nerves because it can be done locally. 
Additionally, an action potential travels down the axon at a particular speed for that 
neuron, depending on the extent of myelination of that nerve. Determining any changes 
in action potential propagation velocity is another way one can assess nerve function, 
especially across a larger area. Therefore, voltage amplitude and velocity are two 
characteristics that are employed in neurophysiology because these characteristics give 
information both locally and across a larger portion of nerve.31 
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It is known that neuropathy can decrease the amount of myelination around a 
nerve.9 The myelin sheath is an insulating layer around the nerve that speeds up nerve 
transmission. In a neuropathic individual, the amount of nerve myelination is less, which 
would ultimately slow down the nerve conduction velocity. In a study of 500 diabetic 
individuals, the motor and sensory nerve conduction in patients with diabetic peripheral 
neuropathy was measured and compared to those of healthy people. It was concluded that 
distal motor latency (DML) in the median and common peroneal nerves in symptomatic 
diabetics was longer than that of asymptomatic diabetics, potentially indicating less 
myelination. The compound motor actional potential (CMAP) amplitude in these same 
nerves was also lower in the diabetic individuals suffering from peripheral neuropathy 
compared to diabetic individuals with no neuropathic symptoms, as shown in Figure 9.32 
 
Figure 9. Motor nerve conduction in diabetic patients with and without peripheral 
neuropathy and in control subjects. Figure 9A is the Distal motor latency (DML) and 
Figure 9B is the compound muscle action potential (CMAP) between symptomatic groups 
(SG), asymptomatic groups (ASG), and control groups (NC). Reproduced from Ref [32]. 
 
Sensory nerve conduction studies were also done in this study of 500 diabetic 
individuals. It was determined that sensory nerve action potential amplitude (SNAP) and 
sensory nerve conduction velocity (SCV) in the diabetic groups (symptomatic and 
asymptomatic) was lower than that in healthy controls. Furthermore, in the symptomatic 
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diabetic group, the SNAP and SCV of the median, ulnar, posterior tibial, and common 
peroneal nerves were significantly lower in the symptomatic group compared to the 
asymptomatic group, as detailed in Figure 10.32 
 
Figure 10. Sensory nerve conduction in diabetic patients with and without peripheral 
neuropathy and in control subjects. Figure 10A illustrates the sensory nerve conduction 
velocity and Figure 10B illustrates the sensory nerve action potential between 
symptomatic groups, asymptomatic groups, and control groups. Reproduced from Ref 
[32]. 
 
Therefore, while conducting neurophysiology tests with the designed microneedle 
array, the latency, action potential amplitude, and conduction velocity are all aspects that 
should be considered when configuring electronics and analyzing data. These three 
characteristics are factors that will be affected by peripheral neuropathy; as a result, 
differences in electrical signals of peripheral nerves between diabetic and control groups 
can be compared to obtain an early diagnosis and track the progression of disease. The 
expected neurophysiological results of the latency, conduction velocity, and the action 
potential amplitude of a diseased versus healthy individual is illustrated in Table 1.  
Table 1. Summary of expected neurophysiological changes between a healthy and 
diabetic individual, relative to each other. 
Characteristic Control Diabetic/Neuropathic 
Latency ↓ ↑ 
Conduction velocity ↑ ↓ 
Action potential amplitude ↑ ↓ 
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Using Mice as a Model of Disease 
 
There are several organisms that are used in research and industry to conduct 
preclinical tests or to model human mechanisms, including mice, zebrafish, rats, 
monkeys, fruit flies, and more. Each organism has its own benefits depending on the area 
of study; for instance, zebrafish are useful in studying the immune system due to similar 
human cell types, such as neutrophils. However, mice are one of the most common 
research animals, and there are several reasons why. Most importantly, mice and humans 
have many of the same genes, and humans and mice develop in the same way from an 
egg and sperm. As a result, the organ systems of mice are closely related to that of 
humans, and this similarity allows researchers to study biological mechanisms and the 
effects on the entire body. Another reason the mouse is used is because of their lifespan. 
Mice live long enough to be able to easily conduct longitudinal studies of chronic 
diseases or aging, but short enough to be reproducible. The small size of mice makes 
them easy to house and maintain for the entirety of their life.33 Also, much is known 
about mice and their genome, so it can be easily manipulated to observe changes, and 
different strains can be more effective than others, depending on the study’s purpose. 
Therefore, in the early stages of prototyping and designing the device, mice will be used 
as a model of disease.33 
In the Townsend Laboratory, mice are used as a model of disease as they develop 
neuropathy either genetically or through administration of a high fat diet. The genetically 
induced neuropathy model is a BTBR ob/ob leptin-deficient diabetic mouse. The BTBR 
model develops severe Type 2 diabetes because the animals are genetically insulin 
resistant. This insulin resistance and other factors associated with diabetes are developed, 
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making the BTBR ob/ob mice a model for disease progression as the diabetes advances 
over the lifetime of the mouse.34 Additionally, the BTBR ob/ob model can be used to test 
the first prototype of this diagnostic device as these genetically altered mice do develop 
peripheral and adipose neuropathy.13 
Mice develop diabetes not only genetically, but also environmentally through the 
administration of a high-fat diet. In a study where mice were fed a high-fat diet for 12 
months, the researchers found diabetic morphologies related to insulin levels, glucose 
tolerance, and more. Therefore, mice can develop diabetes, and consequently peripheral 
neuropathy, while being fed a high-fat diet similar to humans and the Type 2 diabetes 
epidemic.35 As a result, the designed early-diagnosis prototype is using mice for initial 
tests and optimization, and eventually as a method to track disease progression.  
Initially, much work has gone into creating and optimizing a device to use for a 
longitudinal study in the future. The electronic components used must be set up 
appropriately to reduce noise but maximize reproducibility. Protocols, standards, and 
various tests are described and conducted to learn about the needles, software, and 
working with neurophysiology in a practical sense to develop a point-of-care diagnostic 






With the aforementioned project goals, most of the work done for this thesis was 
developing an appropriate protocol to use the new equipment. BIOPAC, the recording 
hardware and software, was new to the Townsend Laboratory; therefore, it was essential 
to get familiar with it and develop a working protocol to take recordings. To do so, much 
trial and error was done with the electrodes using saline agar solution and horseshoe crab 
tissue. The amplifier settings were altered to see how the resulting current was affected in 
many different experiments to further understand the recording signals and how to 
manipulate the hardware. Additionally, much work was put in to understand how to use 
the AcqKnowledge software that is used to look at and analyze the signals. All recordings 
and experiments conducted in this thesis used the developed protocol after much 
troubleshooting and manipulation had been done. 
Furthermore, behavioral protocols to test for disease progression and extent were 
developed and tested. A cold plate test and an acetone test will eventually be used in a 
longitudinal study in mice to behaviorally measure neuropathy, and these tests were new 
to the Townsend Laboratory. After Institutional Animal Care and Use Committee 
(IACUC) approval, these protocols we engineering to eventually be used as a neuropathy 
test. 
Another protocol that was developed as part of this thesis work was to use Luxol 
Fast Blue. This is a stain for myelinated nerves, and again was new to the Townsend 
Laboratory. In order to optimize a staining procedure, many tissues, such as muscle, 
adipose, and sciatic nerve, were stained. All these tissues were stained multiple times 
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with multiple different incubation times in order to optimize the protocol to be used. As a 
result, a large part of this thesis work accomplished its goals for protocol development 
that will be used for experiments and results elaborated on below, but also in the future 




MATERIALS AND METHODS 
 
Materials and Hardware 
 
§ BIOPAC MP160 Data Acquisition Hardware, Part No. MP160WSW 
§ BIOPAC AcqKnowledge® 5 Acquisition and Analysis Software 
§ BIOPAC HLT100C Transducer module 
§ BIOPAC AC150A Power Supply 
§ BIOPAC MCE100C Micro Electrode Amplifier (x4) 
§ Alligator clips 
§ Laptop 
§ VisionTek USB Docking Station 
§ Power strip and power supply 
§ Mini hook leads 
§ Faraday cage 
§ Dissection microscope with light 
§ Custom Microneedles* 
§ Microprobes 0.5 MΩ commercial platinum iridium electrode 
§ Natus Ultra Disposable Stainless-Steel Subdermal Needle Electrodes 
*Due to current intellectual property and the patent process, certain aspects and 






I. Animal Subjects 
 Animals used in this work include Limulus polyphemus, or horseshoe crab, under 
the assistance of Dr. Leonard Kass. Limulus tissue was used to validate the recording 
setup and electronics by using a well-established and well-known nerve model. Mice 
were used with IACUC approval and regulations, detailed in Appendix A. During basal 
recordings tests (no stimulation), mice were anesthetized with 1.5% isoflurane in pure O2 
at a flow rate of 1 L/min and euthanized after nerve recordings by trained personnel.  
 
II. Experimental Setup 
 All recordings were taken in the Faraday cage illustrated in Figure 11. The 
BIOPAC hardware, laptop, and USB docking station are all positioned on a table next to 
the Faraday cage to minimize the length of wires between the recording area and the 
hardware, therefore reducing noise in the recordings. Electrodes that are being used for 
Figure 11. Recording setup with the Faraday cage, BIOPAC hardware, and the laptop 
with the necessary software. Reproduced from Brooke Villinski. 
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recording are connected to red mini-hook leads, detailed in Figure 12, and there are 
marked ground and stimulation electrodes that come from the respective black leads. 
 
III. BIOPAC Protocol for Collecting Recordings 
 There are many functions of the BIOPAC software and hardware, and it can 
execute multiple things both in the collection and analysis of data. There are recordings 
with and without stimulation, both of which are used to collect the data presented in this 
thesis. 
 First, to use the software, turn on the VisionTek external USB connector, the 
laptop, and the BIOPAC MP160 hardware. Insert the teal AcqKnowledge USB into the 
VisionTek connector to have the hardware communicate with the software and laptop. 
When the computer is turned on, open the AcqKnowledge icon on the desktop to open 
the recording software. Create a new experiment, and then open an existing graph 
template file (GTL). The files are named according to their settings, such as the 
stimulation voltage amplitude, duration, or for simple basal recordings. Opening this 
GTL will load the saved settings within the file. Before recording, ensure amplifier 




settings are appropriate on the MCE100C hardware. The standard settings for recording 
with and without stimulation are detailed in Table 2, unless specified otherwise. 
Table 2. Standard MCE100C amplifier settings. 
 
Setting Value on MCE100C 
Amplifier 
Gain 1000x 
Low Pass (LP) 
Filter 
3kHz 
High Pass (HP) 
Filter #1 
100kHz 
High Pass (HP) 
Filter #2 
0.5 Hz HP 
 
 Inside the Faraday cage, the alligator hook leads are set up for recordings by 
placing electrodes in the desired tissue. The recordings are from a differential amplifier, 
so two electrodes are put into the tissue, with a ground to reduce noise. A stimulation 
electrode can also be put into the tissue close to the recording electrodes, but care should 
be taken to ensure all leads are appropriate for their purpose (i.e. differential recording 
and stimulation electrodes lead to the amplifier at the correct position). After electrodes 
are inserted, the Faraday cage can be closed, and “Start” can be selected on the 
AcqKnowledge software. This setup was used to record for all experiments involving 
recordings, with and without stimulation. Different electrodes were incorporated to 
compare among needle types, but the general configuration of the electrophysiology rig is 






IV. Cold and Hot Plate and Acetone Testing 
 
 Part of the platform is to ultimately record electrical signals from the mouse and 
relate the results to already-established measures of neuropathy. Currently, hot and cold 
surfaces are used to test for the presence of neuropathy. If a subject is diabetic, the 
response time will either be slower or completely diminished when exposed to hot or cold 
temperatures compared to a healthy individual. Additionally, chemical tests, such as 
acetone, are used for similar qualitative responses to the acetone being applied to the hind 
paw. In a future longitudinal study with the designed needle array, all three tests will be 
used to relate electrical signals to the progression of neuropathy. These tests were new to 
the Townsend Laboratory, so protocols had to be revised and established to conduct these 
tests. Therefore, part of the project included the development of these protocols. The 
established protocols for the cold plate and acetone tests are shown in detail Appendix C. 
Also, in addition to the protocols, a template for recording data for the cold plate test was 








I. Using Limulus Tissue to Validate the Electrical Setup 
 
Limulus tissue is a well-established nerve model, so the initial experiment was to 
validate the electrical setup and the wire configurations. Additionally, BIOPAC was a 
new software, so a protocol needed to be established on how to use the hardware. Dead 
Limulus tissue was obtained and the custom needles to be used in the future array were 
used for stimulation of the tissue. Standard commercial Microprobes electrodes were 
used for differential recordings, and each needle electrode was positioned as detailed in 
Figure 13. In the experiment, electrodes were moved from one position, termed Setup 1, 
to further apart in Setup 2 in Figure 13 to measure differences in recordings amplitudes.    
 
Figure 13. Electrode setup in dead Limulus tissue to validate electrical configurations 
and observe differences when electrodes are separated by two different distances. 
 
 Sample recordings are illustrated in Figure 14. Setup 1, where the recording 
electrodes were closer together, has a higher signal amplitude compared to Setup 2, 
where the recording electrodes were further apart. This is what was expected as when the 




proof-of-concept test to ensure recording electrodes, wires, and the BIOPAC hardware 
was set up appropriately, and to become familiar with how to use BIOPAC. A protocol, 
detailed in Appendix B, was established as part of this test. Therefore, it can be 
concluded from this experiment that moving forward, the software and hardware setup is 
set up appropriately to measure recordings in tissues. 
 
 
Figure 14. Sample recordings from dead Limulus tissue with electrodes placed in 
different positions in Setup 1 and Setup 2. Setup 1 has a higher voltage amplitude 




II. Using Limulus Tissue to Learn How to Stimulate with the Software 
Basal and stimulated recordings are desired for the final prototype of the device, 
so learning how to stimulate with BIOPAC was essential. The purpose of this experiment 
was to further develop a protocol and become familiar with stimulation using the 
software. Again, Limulus tissue was used because of its reputation as a well-established 
nerve model. Recording electrodes were placed into two ends of the tissue, with a ground 
and a stimulation electrode in between, detailed in Figure 15. The purpose of this 
experiment was to test different stimulation voltage magnitudes to measure any limits in 
voltage signal, to, in the future, stimulate with the lowest possible voltage to minimize 
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risk to the animal. Four stimulation voltage amplitudes were tested: 0.05 V, 0.1 V, 0.2 V, 
and 0.4 V.  
 
Figure 15. Electrical setup used in the experiment to measure different stimulation 
voltage levels. 
 
 Sample recordings from the experiment with different stimulation voltages are 
detailed in Figure 16. As the stimulation voltage increased, the amplitude of the signal 
also increased, as shown in Figure 16A, 16B, and 16C. From Figure 16C and 16D, there 
is a potential saturation in the signal, as there is no observable difference between 0.2V 
and 0.4V stimulation. However, the results are still consistent with what one would 
expect with an increase in the stimulation voltage; therefore, a method to stimulate with 
the BIOPAC hardware and software was established and incorporated into the protocol in 
Appendix B to, in the future, stimulate animal subjects. 
 
Figure 16. Sample recordings from the experiment with stimulation voltages of A) 0.05V, 
B) 0.1V, C) 0.2V and D) 0.4V. As the magnitude of stimulation increased, so did the 
signal, until a plateau at 0.2V and 0.4V. 
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III. Testing the First 3D Printed Microneedle Array 
(array designed and printed by Julia Towne) 
 The first prototype of a device was designed and printed, so the purpose of the 
experiment was to test this design and its dimensions on a euthanized mouse. A mouse 
was euthanized and basal recordings were taken from the shaved scWAT area, with the 
electrodes positioned in the image in Figure 17. The dimensions of the needle array were 
3.5cm x 1.5cm with needles spaced by 5.1 mm apart, with a penetration depth of 1 mm.  
Figure 17. Image of the mouse and needle array positioning that was used in the 
experiment to test design dimensions and recording from a needle array. Array designed 
and printed by Julia Towne. 
In this experiment, basal recordings were taken by moving one differential 
recording electrode around all nine different needle positions in the array. The needle 
positions were labeled according to Figure 18, and all combinations of needles in relation 
to Electrode 1 were tested to determine if noise levels were appropriate to distances 
between needles; again, this was to show that the BIOPAC software and hardware was 




Figure 18. Electrode labels on the mouse that were used in the experiment to test 
different recording positions. 
 
Sample recordings from this experiment are shown in Figure 19. When the 
electrodes were moved to the same needle, Needle 1, the signal canceled out as expected 
in Figure 19A. When the electrode was moved to positions 1 and 2, essentially right next 
to each other, there was an increase in signal, as shown in Figure 19B. The recording 
electrodes were then moved as far apart as possible within the array, to positions 1 and 9. 
As expected, when the needles were moved further away, the noise increased, as detailed 
in Figure 19C. The noise was expected to increase because the recordings were just basal 
recordings, so the amount of tissue between the electrodes increased, thus increasing the 
amount of noise. Therefore, from this experiment, it could be concluded that a needle 




Figure 19. Sample recordings from the first printed device. Electrodes were moved to A) 
Positions 1 and 1, B) 1 and 2, and C) 1 and 9. As the distance between needles increased, 
the amount of noise also increased, as expected. 
 
However, another purpose of the experiment was to test the overall design and 
dimensions of the device. The dimensions of the array that were printed were concluded 
to be too large moving forward, because the needles often moved out of the skin. The 
spacing between needles, 5.1mm, made the array to cover an exceptional amount of the 
entire mouse, even though the scWAT was the target area. The large rectangular design 
on the rounded mouse made needles leave the surface of the skin, causing issues with the 
needle staying positioned on the mouse and needles continuously penetrating the skin. 
Another aspect of the array that could better facilitate needle penetration is increasing the 
depth of needle exposed. In this design, 1mm of needle was exposed to pierce the skin. In 
future prototypes, this could be increased to 2mm to go deeper into tissue and to help 
with maintaining needle penetration for the entire experiment. Additionally, in Figure 17, 
the design featured a large cylindrical rod from the center of the electrode. This rod was 
incorporated into the design with the idea it would help apply even pressure to the array 
when the needles were being inserted into the mouse. However, the rod was unnecessary, 
36 
 
and even obstructed the movement of some electrodes around the array. As a result, from 
the initial tests of the device, can be concluded that the dimensions of 3.5cm x 1.5cm 
with needles spaced by 5.1 mm apart and a penetration depth of 1 mm is not suitable for 
future designs. The array should be shortened with needles positioned closer together, 
and with the rod from the center removed. This experiment was important and 
informational for determining and testing design dimensions to move forward with 
designed and printed prototypes.  
 
IV. Basal Mouse Recordings to Compare Needles to Commercial Needles 
 
The first prototype of the design uses needles that are not currently used for 
recording electrical signals in tissue. As a result, it is essential to learn about these 
needles and to compare these needles to commercially available electrodes that are used 
for neural recordings. The purpose of this experiment was to use an anesthetized mouse 
to obtain basal recordings of the subcutaneous adipose tissue using both the design 
needles and commercially available needles to compare signals between the two. 
Amplifier settings were also modified with the needles in the tissue during the 
experiment to further understand how high and low pass filters affect signal. 
 First, one recording custom needle was inserted into the scWAT of the mouse, as 
shown in Figure 20. The other differential recording electrode, not shown in the figure, 
was inserted in the base of the tail. Recordings were taken with the standard amplifier 
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settings but were changed throughout the procedure to try and reduce noise of the 
produced signals.  
 
Figure 20. Custom needle recording setup used in the experiment to get basal signals 
from an anesthetized mouse. 
 
After recordings were taken from the custom needles, the recording electrode was 
switched to a 0.5 MΩ commercial platinum iridium electrode from Microprobes, where 
the electrode details are shown in Figure 21.  
 
Figure 21. Microprobes recordings electrode that was used to compare to custom 
needles in an anesthetized mouse. 
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The electrical setup was the same for the Microprobes recordings as the custom 
design needles. One recording electrode was placed at the same location in the scWAT, 
and the other recording electrode placed in the tail, as detailed in Figure 22. The 
Microprobes for Life Science is a company that focuses solely on neural microelectrodes, 
needle arrays, and more. The needles from Microprobes are distributed worldwide for 
neural recordings, so these electrodes were selected as a comparison to check the quality 
and reliability of signals from the custom needles.  
 
Figure 22. Microprobes setup showing the two differential recording electrodes, with one 
in the tail that stayed constant throughout the experiment. The other needle was switched 
with the custom needles for comparison. 
 
The Microprobes needles used in this experiment are not beveled like the custom 
needles are, so inserting them into the mouse tissue was much more difficult. Mouse skin 
is very flexible, so upon insertion of the needle, the skin had to be pulled quite taut for the 
needle to even slightly penetrate the skin. The custom electrodes are three-beveled 
needles, which makes insertion into the tissue much easier. As a result, comparing 
electrical recordings from these two needles is difficult, given the Microprobes needles 
may not have even penetrated the tissue. This is a consideration that is important to 
consider for future iterations of the designed prototype, given that beveled needles are 
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much easier to work with compared to already available needles. The design, then, should 
incorporate beveled needles when being put into an array to record electrical signals 
faster and with more ease. 
 
V. Natus and Custom Needle Basal Recordings in Anesthetized Mouse 
 
 An important aspect of the design platform is to make sure the custom needles 
that will be used will be comparable to other needles, and yield results like what one 
would expect. The objective of this experiment was to compare the feasibility of 
collecting basal recordings from a set of commercially available needles to the custom 
needles in an anesthetized mouse. Natus needles are currently used in nerve conduction 
velocity tests, so they are a well-established comparison. This comparison between the 
two needle types was done in three different tissues to determine if there are any 
differences between the two needles, or any differences between tissue types. The tissue 
types tested for each needle was the scWAT, muscle tissue, and the paw. Subcutaneous 
white adipose tissue and the paw are two areas that will be tested in the future with the 
first fully developed prototype because these two areas are prone to peripheral 
neuropathy. A sample of the electrical setup in the scWAT tissue is illustrated in Figure 




Figure 23.Sample image from the experiment tested different tissue types with custom 
needles inserted in the scWAT. 
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 Electrical signals from the muscle were tested in the experiment to compare 
neuromuscular junctions between needles. The neuromuscular junction is a very well-
studied and well-understood electrical signal, so relating signals between the electrodes 
would be suitable. Another purpose of this experiment was to further reduce noise levels 
inside the faraday cage, as this is one of the most critical aspects when recording from 
nerves. The neuromuscular junction, then, would ideally give insight on how much noise 
must be further tested and reduced. 
 From this experiment, it can be concluded that both the Natus needles and the 
custom needles are similar in how easy they are to work with. The custom needles, as 
previously mentioned, pierce the skin fairly easily. The Natus needles pierced better than 
previously used commercial electrodes, but still not as well as the custom needles. The 
recordings that were collected during this experiment exhibited sinusoidal noise from the 
environment. Therefore, this experiment was another attempt to further reduce this noise 
from the signals to clearly detect an action potential.  
 
VI. Invertebrate Leg Test to Compare Signals with Custom Needles 
(experiment conducted by Brooke Villinski using the developed protocol) 
 Crickets are another well-established nerve model, similar to the horseshoe crab 
used in previous experiments. Due to a shortage of horseshoe crabs at the time of the 
experiment, crickets were used to test the custom needles compared with the Natus 
needles. Crickets were used due to simplicity, but also because they are inexpensive and 
readily available. The cricket as a neurophysiology model works by external sensory 
structures, called cerci. The cerci are like antennae and can be mechanically stimulated to 
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produce action potentials. Mechanically stimulating nerves can be done in many ways, 
some of which include vibrations, pressure, and touch.36 For the purposes of comparing 
the custom needles to commercial needles, this factor was useful to not have to rely on 
the BIOPAC software for stimulation, but also to simplify the experiment’s required 
technology. 
 Based on the procedure adapted from Dagda et. al., a cricket leg test was 
conducted to compare the two needles. The recording electrode was inserted in the coxa, 
and the ground was in the tarsus; these are two of the four segments of the cricket leg. 
The cricket leg was mechanically stimulated with a blow of air from the experimenter. 
The experimental setup for the Natus needles, which was similar to the custom needles, is 
illustrated in Figure 24, where the electrode positions in the cricket leg are shown.  
Figure 24. Experimental setup for the cricket leg test with the Natus commercial 
electrodes pictured. The nerves were stimulated mechanically, with the recording 
electrode in the Coxa and the ground in the Tarsus. Reproduced from Brooke Villinski. 
 
 The overall purpose of this test was to relate the results with the Natus electrodes 
versus the custom electrodes as a “first pass” to compare recording performance. The 
results from this experiment, are detailed in Figure 25, where Figure 25A is with the 
Natus needle and Figure 25B is with the custom needle. The blue line indicates the start 
of stimulation, which is why there is an increase in signal following it.  
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 From this experiment, it can be concluded that the noise levels are comparable 
between the two, averaging about 12mV for both; this could indicate the needles behave 
similar in the tissue. For the custom electrode, the response after stimulation is larger. 
This could be because the custom needles are truly more sensitive than the commercial 
comparison electrode. However, it should be taken into consideration that the stimulation 
during this experiment was fairly uncontrolled. The puff of air could have been stronger 
for the test with the custom electrode, which could have stimulated more nerves and thus 
increased the resulting signal. As a result, for this test, a good comparison of the 
recording performance is the signal noise amplitude to show similarities in needle 
characteristics such as resistance and conductivity. The signal noise amplitudes are 
comparable between the two needles, which was a first pass to ensure the custom needles 
work as well or better than commercially available nerve conduction study electrodes. 
Therefore, more tests with a mouse can be done to further validate the custom needle 




Figure 25. Results collected from the cricket let experiment with A) a Natus electrode, 
and B) a custom needle. The noise levels are comparable between the two needles. 
Reproduced from Brooke Villinski. 
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VII. Sciatic Nerve Stimulation in an Anesthetized Mouse 
(experiment conducted by Brooke Villinski using the developed protocol) 
 Before recordings are taken from the scWAT and paw, areas of the mouse that are 
not widely studied for nerve conductance, well-studied areas were ideal to start with 
officially comparing the custom needles with commercially available electrodes. In this 
experiment, the mouse’s sciatic nerve was exposed and the custom needles and Natus 
needles were both used to take recordings using this well-studied nerve being stimulated. 
Single needles were used as opposed to needles being in an array, and the ground 
electrode was inserted into the tail. The sciatic nerve was stimulated with a Natus needle 
for both recording electrode types, and recordings with both the Natus needles and 
custom needles were taken from the plantar paw with the ground electrode in the tail. The 
purpose of this experiment, like previous experiments, was to compare recordings in a 
mouse between the custom needles and well-established needles. 
 This was the first experiment from an anesthetized mouse that clean action 
potentials were able to be distinguished from the recordings because the noise level issue 
had been mitigated. The mouse was stimulated with 50mV, and the amplifier was set to a 
200x gain. The stimulation was tested prior to testing the needles in the mouse tissue to 
ensure stimulation was actually occurring. Figure 26A shows the signal from the Natus 
needle recordings, and Figure 26B shows the recordings taken with the custom needle 
electrode. The blue line indicates the time of stimulation, which creates the large increase 
in signal. The drop in signal shortly after is from the differential amplifier, and the 
following rise in signal is a compound action potential (CAP), indicated in the figure. 
CAPs are the summation of multiple different action potentials as it is an extracellular 
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recording, which makes sense in the context of the recordings taken. The amplitude and 
shape of signals are very similar between the two electrodes, which was a positive 
outcome given that the custom electrodes are not typically used for nerve recordings. 
 
Figure 26. Action potentials recorded from the experiment. A Natus electrode was used 
for stimulation, indicated with the blue line, and the recording electrodes from A) Natus 
needles and B) custom needles. The signals are very similar between the two needles. 
Adapted from Brooke Villinski. 
 
 Another recording that was taken from this experiment is testing a custom needle 
inside an array. The same setup was used with the Natus needle in the sciatic nerve for 
stimulation, but the recording custom needle electrode was inserted within an array to 
ensure the array components did not affect signals. Figure 27 is sample data from this 
experiment, where the blue line again indicates the time of stimulation. A similar CAP is 
observed that is similar in shape and size to the standalone custom needle in Figure 26B.  
 
Figure 27. Action potential recorded after stimulation with a custom needle within an 
array to determine if signals are affected when inserted into the array. The signals of the 






 Overall, from this experiment, it can be concluded that stimulated recordings can 
be taken from an anesthetized mouse, and the signals between commercially available 
needles and the custom needles to be used in the future array are comparable. 
Additionally, the needle array itself does not affect the quality, shape, or amplitude of 
signals using the custom needles.  
 
VIII. Stimulation of Anesthetized Mouse with a Functioning Array 
(experiment conducted by Brooke Villinski using the developed protocol, array designed 
and printed by Julia Towne) 
 The previous experiment tested a working protocol with minimal signal noise to 
stimulate an anesthetized mouse. The next step in validating the array concept is to test 
recordings from multiple needles held in the array. A similar prototype that was used in a 
previous experiment in testing the array was used where nine electrodes are used with a 2 
mm needle penetration depth. The needles were arbitrarily numbered, and one electrode 
was used for stimulation. Recording pairs within the array were grouped to evaluate the 
quality of signals in an array, as indicated in Figure 28. 
 
Figure 28. Schematic detailed the recording pairs and the stimulation electrode where 




 Essentially, the goal of this experiment was to record four differential electrode 
pairs and to stimulate with the ninth needle in an array. The ground electrode was placed 
in the tail, and the needle array was inserted into the shaved scWAT tissue. A printed 
circuit board (PCB) was used to wire the electrodes to the amplifier to make handling the 
array with the mouse easier in future experiments. The PCB with the array in the scWAT 
of the mouse is illustrated in Figure 29, again with the differential pairs indicated by 
color. 
 
Figure 29. Array setup for the experiment to record from four differential pairs with a 
PCB board in a needle array. The mouse was anesthetized and recordings taken from 
each of the color-indicated recording pairs to determine if array recordings are possible. 
Reproduced from Brooke Villinski. 
 
 The results from the experiment are encouraging for pursuing recordings with the 
selected custom needles. Sample recordings from all differentials are detailed in Figure 
30, with the blue line indicating the stimulation time. The large spike followed by the 
large drop in signal is due to the stimulation and the differential amplifier; however, the 
increase in signal after are compound action potentials. The blue and pink electrode pairs 
closer to the stimulation needle, aside for the red pair, show higher signals compared to 
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the green pair that is further away from the stimulus. This is what one would expect given 
that needles further away from the stimulation have more distance to lose signal to the 
surroundings. The green pairs in the array could be too far away from the stimulation 
needle to yield an action potential from surrounding nerves; the needles in future 
iterations could be closer together to determine the maximum amount of distance 
between needles to still get meaningful recordings.  
 
Figure 30. All recording data collected from the needle array experiment. Differential 
pairs are indicated by color. As the distance from the stimulation electrode increases, the 
CAP signal decreases, as expected. Reproduced from Brooke Villinski. 
 
 There are several different factors that could have affected the results for the red 
differential pair. The red differential pair was close to the stimulation needle, so it is 
possible it was along the same nerve bundle. This could have affected the results of not 
obtaining an action potential by being oversaturated with the stimulation voltage. 
Additionally, it is possible these electrodes were not fully penetrating the tissue, so the 
stimulation response from the nerves in this area was not captured. However, despite this 
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discrepancy of this differential pair, from this experiment, it can be concluded that 
recording from an array is possible. The overall magnitude of measured compound action 
potentials decreases the further away from the stimulation needle, as expected, so more 
experiments can be conducted to further push the progress of a longitudinal study of 
diseased mice. 
 
Summary of Results 
 
From the series of experiments conducted thus far, several critical conclusions 
were made. First, much has been learned about BIOPAC and what the final needle array 
will look like. In terms of needle dimensions, the needles should be put as close together 
as possible to make the overall array smaller. A rod in the center of the array to apply 
constant pressure is unnecessary, but the idea of a holder for the needles to sit in is 
important. If the needle array is simply just a holder for the needles, then the array can be 
sanitized and used many times simply by just switching out the needles. Additionally, 
because of the needle holder, a cap to cover the needles is another design aspect that 
should be considered so the electrodes do not fall out of place. More dimensions of arrays 
should be tested to further optimize the shape and usability for a final prototype.   
 Furthermore, protocols and familiarity with new hardware and software had to be 
established. The BIOPAC software and hardware was selected due to its reproducibility 
and sensitivity, as well as its broad range of capabilities and features. However, BIOPAC 
has not necessarily been used for the purpose of recording from small nerve fibers, so 
limits of sensitivity had to be configured. Detection limits and sensitivity of the 
amplifiers are important when considering the unknown size of action potentials that will 
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be collected from the peripheral areas. Understanding how the amplifier and detectors 
function, as well as the types of signals they collect, will be important downstream in the 
process to compare nerve signals between mice and between a diabetic and healthy 
mouse. From this project, working BIOPAC hardware and software protocols have been 
developed and tested, so both basal and stimulated recordings from mice are possible.  
 More work needs to be done to establish an optimized design, and many things 
must be considered when designing the device, including constraints in 3D printing 
capabilities, dimensions of the needles, the electrical characteristics of the needles 
themselves, and more. Most of the start of this project has been developing protocols to 
use the software and hardware to record signals, as well as comparing needles and array 
dimensions. This mostly includes testing more 3D printed arrays and looking more into 
how recordings from a needle array will be done. A couple of arrays were tested as the 
first attempts to do so, but more should be tested to optimize the design. In one 
experiment, one needle was used as a reference electrode, so this is something that can be 
incorporated into future array recordings. The distances between needle electrodes will be 
important for analyzing data and understanding the electrical signals that are collected, 
too, as the signals change with distance. Overall, before a longitudinal study is 
conducted, more needle arrays should be tested to verify and optimize the device.  
 Another aspect of the platform is determining how the data will be used and what 
measure will be best suited to comparing electrical signals. In nerve conduction studies, 
typically the nerve conduction velocity and the nerve amplitude voltage are used. These 
measures could work but incorporating them into the developed system to establish 
baselines and eliminate noise from the signals will require additional investigation. 
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 Other small portions of the project include tissue staining and imaging familiarity. 
The Townsend Laboratory had never used the Luxol Blue stain before, so after receiving 
this stain, part of the project to design this platform was to develop a procedure for 
staining the tissues to look at myelinated nerves. To do so, several attempts were made 
with different incubation times and tissue types with the stain to optimize and then image 
with brightfield microscopy. Furthermore, as the device will eventually develop into a 
startup company, several Maine Innovation, Research and Technology Accelerator 
(MIRTA) meetings were attended. These meetings focus on commercialization, 
understanding the consumer and audience, as well as outreach to establish an effective 
startup company and device from a business perspective. 
Overall, the objective of this project was to start the process of developing a 
platform for creating a device to detect peripheral neuropathy earlier than it currently is. 
Many protocols were established and optimized in order to become familiar with 
hardware and software needed to record electrical signals. Additionally, needle 
prototypes were tested, and several attempts were done to characterize the needle’s 
properties. Determining an optimal needle and array dimensions are things that are in 
progress for a final prototype of a design. The work conducted and illustrated in this 
thesis have provided a way to collect signals, an attempt to understanding the signals, and 






There is an increasing need for peripheral neuropathy detection in a clinical 
setting. The growing obesity epidemic has made nerve death at the limbs an increasing 
health concern that holds much importance worldwide. The eventual goal of the project is 
to create a device to ultimately detect peripheral neuropathy sooner than it is currently in 
the clinic, but this is an iterative process where many things must be considered. The 
protocols and experiments conducted thus far for designing the platform to do so are just 
the first steps in the process to create a working device. The design of the device will 
incorporate a needle array and a longitudinal study of mice with diabetes will assess the 
quality of this array in comparison with other methods.  
 The recordings that are typically conducted in both mice and humans are those 
from large nerves, such as the sciatic and the sural nerve. Not many individuals have 
attempted to record from small nerve fibers in areas such as the paw, but there is 
comparable literature for recording in an array in these larger areas of the peripheral 
nervous system. With standard-of-care devices and techniques, and even typical nerve 
conduction studies, the designed device will be comparable. Similar recordings and 
measurements are taken, as particular action potentials are distinguished in recordings 
after stimulation with the custom needles. Diabetes can be diagnosed with a NCV study 
with measurements such as the SNAP amplitude given that nerve stimulation induces an 
action potential of a given magnitude, and such can be compared to a healthy 
individual.32,37 As a result, the designed device is comparable as the action potential 
amplitudes acquired can be compared in a similar fashion to NCV studies, so a diagnosis 
between healthy and diseased individuals is possible.  
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 In addition, it was proven that muscle tissue can be stimulated and recorded from 
with the custom needles. Another aspect of the standard of care for diagnosing peripheral 
neuropathy refers to the CMAP.37 Compound action potentials were collected in the set 
of experiments and muscle tissues were target tissues because they are so well 
understood. Although the neuropathy is far along by the time it reaches the muscles, in 
the initial stages of the device for proof-of-concept, it is critical to compare the CMAP 
amplitudes recorded from the custom needles to those taken from commercial electrodes, 
such as the Natus needles that are used in nerve conduction studies. This comparison 
would yield similar data, as recording components thus far are comparable to data 
collected based on the diagnostic standard of care of peripheral neuropathy.  
 In addition to being comparable to the standard of care for diagnosis, there are 
researchers working to record from a needle array. Particularly, some of these electrodes 
that record from peripheral areas are “cuff electrodes”; essentially, there are microneedles 
or a conductive pad that is encompassed in a cuff that can be wrapped around a wrist, 
ankle, arm, etc. However, maintaining the positioning of these electrodes is an issue for 
sustained recordings, and there are sensitivity challenges.38 Compared to these cuff 
electrodes, although desirable due to ease of use and ability to customize, the designed 
device would likely serve a similar function but improve on areas the cuff electrodes fall 
short in. For example, when using standard NCV study electrodes such as the Natus 
needles, similar sensitivities and noise levels were recorded between the commercial and 
custom needles. The Natus needles are more sensitive than cuff electrodes because of 
their overall purpose, and because the custom needle arrays are comparable to the Natus 
needles, the custom needle array design improves sensitivity while still being easy to use. 
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As a result, the custom needle array would be the middle ground between cuff electrodes 
that are not sensitive enough and the NCV needles that are painful and invasive.  
 There are a variety of flexible microneedle arrays depending on the fabrication 
material, and cuff electrodes are just a subset of such. Specifically, flexible microneedle 
arrays are used for at-home bio-signaling; these signals include other standard of care 
measurements for diagnosing peripheral neuropathy, like an electromyogram. A benefit 
of flexible microneedle electrodes not positioned as a cuff is for better electrode 
positioning and stability. These electrode arrays can be bent in any shape to conform to 
the subject’s skin which enhanced electrode penetration.39 The designed device thus far is 
made of rigid 3D printed materials, but making the array flexible is a potential 
improvement for the future. If the array backing for the custom device is flexible, this 
could allow for better recordings to be taken given, for instance, the curvature of the foot. 
A cuff electrode would not be suitable for the tapered shape of the foot, but a flexible 
electrode would morph to the curvature of the ball of the foot for earlier detection of 
nerve malfunction. 
 Another aspect of microneedle electrode arrays that are currently used have a 
varying needle heights. The Utah Slant Electrode Array features microneedles with a 





Figure 31. Utah Slant array highlighting the differences in needle heights. Reproduced 
from Ref [40]. 
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 With this slanted electrode setup, peripheral nerves are targeted. However, 
experiments with this electrode focus on the sciatic nerve and not the areas the custom 
device will focus on such as the paw and scWAT. In studies with the slanted array, there 
is stimulation over a time course to track the threshold measurements after insertion.40 
This is comparable to the custom needle array as similar recordings will be taken with 
stimulation. From these commercial electrode arrays, the potential for different needle 
heights could be proven beneficial. If the needle array could penetrate the skin layers, the 
underlying adipose, and then muscle tissue, the progression and severity of neuropathy in 
the area could be evaluated. Instead of one electrode height where the electrodes 
penetrate one tissue type, incorporating different needle heights would allow for 
recordings from each tissue for a more well-rounded diagnosis. Peripheral neuropathy 
moves from the skin inward, and neuropathy is evident in the adipose tissues.13 Slanted 
needle heights in the custom device to penetrate the underlying adipose tissue, as well as 
other tissue types, would improve the overall quality of the device and understanding of 
the disease in general. 
 An important component to that makes microneedle arrays desirable is the ability 
for these electrodes to be available for at-home use. With an increasing aging population, 
microneedle arrays will hopefully reduce the need for long-awaited doctors visits, but 
also reduce preparation time for any gel or lubricants for larger, more invasive 
needles.39,41 The designed microneedle array will be easy to use and implement for an 
individual and be much less invasive. The goal is to make custom design able to fit in the 
palm of one’s hand so it would be portable, lightweight, and efficient. These standards 
are crucial for microneedle arrays as the small size and scale make these arrays desirable. 
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To compare in a competitive commercial market, the device must be at least the same 











 Once a working prototype is established, there is a clear direction moving forward 
on a longitudinal study to track the progression of diabetic mice compared to healthy 
mice. Young mice will be used, and the disease progression will be tracked using many 
different diagnostic methods. As previously mentioned, the Townsend Laboratory has 
established both a genetic and environmental mouse model of mice that will develop 
peripheral neuropathy. Therefore, starting out, young mice that will develop neuropathy 
either by genetics or by environmental causes, like a high fat diet, will be compared to 
healthy mice. 
 There are several different methods that will be used to track the progression of 
disease. A Von Frey test is one currently used in the Townsend Laboratory and in the 
clinical diagnosis of neuropathy. It involves filaments with varying forces that are 
pressed against the mid-plantar surface of the mouse’s paw. The amount of force and the 
time the animal takes to react to the force is used as a relative measure of neuropathy. 
The Townsend Laboratory frequently uses this method for neuropathy progression and 
diabetic studies, so standard and diseased baselines with this test are known. As a result, a 
Von Frey test will be used in a series of others to track the progression of disease. 
 Protocols that were established in this work for a cold plate and acetone test are 
other measures of neuropathy that will be utilized. A cold plate and acetone test are like 
the Von Frey, where the animal’s reaction to each is recorded. Any delayed or unusual 
responses would be indicative of some extent of nerve death. Each of these behavioral 
tests—Von Frey, cold plate, and the acetone test—will be used to compare to the 
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electrical signals obtained from these mice. Ideally, these tests, in conjunction with 
electrical signals from the developed protocols, would be conducted once a week over the 
course of several weeks. Additionally, some mice will be euthanized throughout the study 
and their tissues collected as a small portion of the project was to become familiar with 
different staining techniques. Luxol Blue is a myelin stain, so this could track the 
progression of demyelination that occurs with peripheral neuropathy. The myelin that 
surrounds some nerves will stain blue, and the surrounding tissue will be a clear white, as 
detailed in Figure 32, which shows an image stained with Luxol Blue from the scWAT. 
 
Figure 32. Image from the scWAT tissue of a mouse stained with Luxol Blue. Both blood 
vessels and myelinated nerves can be distinguished in tissues stained with Luxol Blue. 
 
  PGP9.5 is another stain that will be used after tissue collected. PGP9.5 is a pan-
neuronal antibody stain, so all nerves in the tissue will be stained, as shown in Figure 
33.42 As a result, nerve death can be compared at different stages of disease with the 





full picture at the tissue level of the underlying adipose nerves. The results from the 
staining can then be compared to the electrical recordings and behavioral tests to give a 
functional, behavioral, and pathological comparison of peripheral neuropathy.  
 
Figure 33. PGP9.5 antibody pan neuronal marker. Reproduced from Ref [42]. 
 
In the near future, a longitudinal study will be conducted using mice as a model of 
disease to identify the sensitivity and quality of the designed device as a diagnostic tool. 
The work conducted is part of a bigger picture to attempt to diagnose peripheral 
neuropathy earlier in the clinic by using a less invasive and painful method. In doing so, 
hopefully the peripheral neuropathy worldwide presence can be better understood, 
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BIOPAC Recording Protocol 
 
BIOPAC SOP 
EM & JWW  
Updated July 23rd, 2019 
 
SECTION I – Set-up and Recording 
White cord: stimulating needles, which are connected to black leads 
Red alligator hook leads: differential recording needles, labeled with “+1” and “-1” 
 
Software Start-up: 
1. Turn on VisionTek external USB connector (back right). 
2. Turn on laptop (right) with usual Townsend lab password. 
3. Insert teal BioPac USB into VisionTek USB reader. 
4. Turn on BioPac on MP160 (in the back on BioPac hardware all the way to the left) 
5. When computer is on, open AcqKnowledge icon on desktop. 
a. NOTE: if at this point an error occurs, try bypassing the VisionTek by 
plugging the black BioPac USB cord and teal BioPac USB directly into the laptop. 
Restart BioPac and software. 












7. Select the “Create new experiment” and then open an existing graph template. 
Examples of existing templates: 
a. Basal Recordings: “2channelMCE100C_test2”  
i. NOTE: there is no “stimulation” in the name  
b. Stimulation: “2channelMCE100C_Stimulation_0.2Volts_2msec pulse 
i. NOTE: stimulation voltage and length of stimulation pulse can be 




Acquiring Recordings:  
8. In the Faraday cage, for recordings, open the alligator hook leads and clamp in the 
desired electrodes 
9. Using the manipulator, insert the electrode into the tissue. 
10. Insert the other red differential wire with the desired electrode into the sample. 
a. NOTE: the +1 lead and -1 lead labeling does not matter for which 
electrode is which because the amplifier will just measure. These red 
leads with +1 and -1 are RECORDING needles, so they will be needed 
for basal and recording needles. 
 
11. If stimulating, follow the thicker white cable (looks like a phone jack) into the cage 
from the amplifier. Insert the black stimulation lead labeled “signal,” and this 
electrode is where stimulation will come from. 
a.  NOTE: the green wire that extends from the larger white wire is the 
stimulation ground. Only use if necessary, i.e. signal is noisy and 
trying to reduce noise by trial and error. 
 
12. Insert the black lead from the cage labeled “ground” into an appropriate position 
on the sample. 
13. Close the Faraday cage if possible. Press “Start” (top left of software) if needles 
and electrodes are accurately placed.  
14. Settings (i.e. high/low pass filters, electrode positioning) can be changed 
throughout, but the times where things are changed should be recorded. There is a 
stop bottom where start in the top left was clicked that will stop collection if 
necessary. 
15. Save the data as follows:  
a. Basal recordings  
“INITIALS_date_file description”  
ex. “EM_14dec2019_2 needle recording array dead mouse” 
b. Stimulation 
“INITIALS_date_file description 
ex. “EM_14dec2019_BD needle stimulation dead mouse” 
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16. After recording and saving data, if conducting another experiment, close out of 
AcqKnowledge and reopen the GTL template. 
 
Close Out of Software:  
17. Close AcqKnowledge icon 
18. Eject BioPac teal USB on the laptop and remove from VisionTek. 
19. Turn off BioPac MP160 hardware, VisionTek USB reader, and laptop. 
 
SECTION II - Manipulating Software and Tips 
Modifying Stimulation and Pulse: 
1. Select MP160àSet up data acquisitionàstimulation (top left of software) 
2. Change the voltages and the timing in between intervals as needed. 
a. NOTE: for changes to be applied the run must be stopped and 
started again 
b. Below are two examples of settings  
Segment # Voltage (V) Time (ms) 
1 0 100 
2 0.2 2 
3 0 100 
4 0.2 2 








Segment # Voltage (V) Time (ms) 
1 .05 2 
2 0 300 
3 0 0 
4 0 0 
5 0 0 
Example of what yielded positive results for sciatic nerve in mouse. A single 
0.05 V, 2 ms pulse followed by a 300 ms delay. 
Example of dual 0.2 V, 2 ms pulses with alternating 100 ms and 200 ms 
delays. This is what was being used previously. 
67 
 
3. Save as template with a new name with the given settings that were changed. 
a. For example, include the stimulation and voltage magnitude in 




1. Adjusting Voltage Scale (y-axis)  
a. Double-click y-axis 
b. Popup screen will appear. 
c. Adjust scale anywhere from 1-15 V depending on size of signal 
and or noise. 
2. Adjusting Time Scale (x-axis)  
a. Double-click y-axis 
b. Popup screen will appear 






COLD PLATE PROTOCOL 
 
Cold Plate Test Protocol (Thermal Allodynia) 
Adapted from Van der Waal et al. 2015 
EM Updated February 2019 
 
1. Cover the bottom of the Von Frey apparatus with aluminum foil and tape to the 
sides of the apparatus. Ensure the mouse’s feet can still be seen past the tape and 
aluminum foil. 
2. Determine the number of experimental subjects and place each mouse into its own 
area within the Von Frey apparatus. Allow acclimation for 15-20 minutes. 
a. NOTE: Make sure to properly label each compartment with the necessary 
mouse information (i.e. any identifying markers: mouse ID, ear punch, 
sex, etc.) 
3. Place the entire Von Frey enclosure into a bucket containing ice with a thin layer 
of aluminum foil across the top of the ice and record the time. 
4. Using a stopwatch, observe and record the time at which any of the potential 
reactions listed below occur, being sure to record any corresponding intensities 
for each reaction: 
a. Lifting of the paw or on hind legs 
b. Scratching of the paw 
c. Touching side of hip or paw depending on side of paw administration 
5. Record the time that the cold plate reaches 2-2.5 ºC. 







Cold Plate Test Data Recording Template 
 
 
Figure 34. Cold plate test data recording template. There are areas for specific information 
about the study, such as the mouse ID and project. The time when the mouse was put on the cold 
surface is recorded, and the time when the cold plate reaches the proper temperature. There are 
time boxes for the lifting of paw/on two feet behavior that can be shaded accordingly when the 
mouse performs that behavior. Other times for other less frequent behaviors can be recorded, as 





Mid-Plantar Surface Target 
Acetone Touch Test Protocol 
 
Neuropathy Acetone Test 
Adapted from Vissers, et. Al (2005) 
EM Updated February 2019 
 
1. Determine number of experimental subjects and place each mouse into its own 
area within the Von Frey apparatus 
a. NOTE: Make sure to properly label each compartment with the necessary 
mouse information (i.e. any identifying markers: Mouse ID, Ear Punch, 
Sex, etc.) 
2. A total of 12 mice may be tested at once, but be sure to allow each mouse 
approximately 15-20 minutes to acclimate to the mesh flooring before testing 
a. NOTE: Mice have acclimated when excessive movement and grooming 
have ceased. 
3. Set up video camera so the mice can be seen 
4. Fill a 1 mL Tuberculin syringe with acetone and gently push the syringe until a 
small bubble forms at the top of the syringe 
5. Start recording on the camera. Gently apply the acetone to the plantar surface of 
the hind paw (see diagram below), making sure to only touch the mouse with the 
acetone bubble formed at the top of the syringe. 
  
6. Observe each mouse for any of the following acetone evoked behaviors: 
a. Paw elevation 
b. Flinching 
c. Licking  
d. Scratching 
7. Using the video camera, record how long these acetone evoked behaviors are 
present for a minimum of 0.5 seconds (for the brief normal response) to a 
maximal cut off of 20 seconds (Choi et al. 1994) 
a. NOTE: Time 0 begins when the acetone is applied and stops when the 
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